

Appendix 4D Half-Year Report

Rule 4.2A

Appendix 4D Half-Year Report

1. Company details

Name of entity

Pro Medicus Limited									
ABN or equivalent company reference	Financial half year ended ('current period')	Financial half year ended ('previous period')							
25 006 194 752	31 December 2016	31 December 2015							

2. Results for announcement to the market.

The information in this report should be read in conjunction with the 30 June 2016 Annual Financial Report.

ASX Listing Rules Ref		2016 A\$'000	20 A\$'	15 000	% change	
2.1	Revenue from ordinary activities	15,202	14,2	285	6.4%	
2.2	Underlying Profit before Tax (minus one- offs and currency gains)	5,877	5,063		16.1%	
	One-offs (Employee entitlements, redundancy costs, legal)	-	(75	54)	N/A	
	Currency gains	1,032	17	71	503.5%	
	Profit for the period from continuing operations before tax	6,909	4,4	80	54.2%	
	Profit/(Loss) from ordinary activities after tax attributable to members	4,796	2,9	941	63.1%	
2.3	Net Profit/(Loss) for the period attributable to members	4,796 Up 63.1%				
	% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.					
2.4	Dividends (distributions)	Amount per security Unfranked amount per security				
	Unfranked dividend amount per security					
	Final Dividend Previous corresponding period	1.5 cents 1.0 cents			1.5 cents 1.0 cents	
	Interim Dividend Previous corresponding period		1.5 cents 1.5 cents		1.5 cents 1.5 cents	



Appendix 4D Half-Year Report

2.5	Record date for Interim dividend Interim dividends payment dates	10 March 2017 24 March 2017				
2.6	REVIEW AND RESULTS OF OPERATIONS					
	The Company reported a first half after tax profit of \$4.80m, an increase of \$1.86m (up 63.1%) compared to the same period last year. Revenue for the 6 month period of the Company increased from \$14.28m to \$15.20m, an increase of 6.4%.					
	The result from the underlying operations for the period was a profit of \$4.08m compares to an underlying profit of \$2.82m from the previous corresponding period, an increase 44.7% (The underlying profit is made up of reported profit after-tax of \$4.80m and subtracting the after-tax net currency gain of \$0.72m (Dec 2015: \$0.12m)).					
	During the period the Company continued to make strong inroads into the North Americ market winning a \$18.0m contract with Mayo Clinic, one the most recognised health systems in North America as well as globally. The Company made significant progress with its installations with all key implementations being on or ahead of schedule.					
	The Company is looking to further build on its presence in North America and is actively pursuing key opportunities both within the enterprise imaging/large teaching hospital and private imaging centre markets.					
	 The Company's European business performed in line with expectations. A capital sale of \$1.5m in the previous corresponding period was not repeated in the current half. The company's Australian business improved as a result of increased adoption of the Visage RIS and Visage PACS products. Promedicus.net, the company's e-health offering, continuing to perform well throughout the period despite increasing competition. The Company continued its significant investment in R&D, both in Australia as well as overseas. The company's cash reserves have increased by \$3.17m for the 6 month period with cash reserves of \$20.28m at the end of December 2016. The company remains debt free. 					
	The Board is of the view that there are sufficient cash reserve growth of the business from internal sources. As a result the an unfranked interim dividend of 1.5c per share.					
3.	Net Tangible Assets per security Net Tangible Assets per security	2016 2015 \$0.21 \$0.16				
		ψο.το				
4.	Details of entities over which control has been gair period	ned or lost during the				
	There are no entities over which control has been gained or lost during the period.					



Appendix 4D Half-Year Report

5.	Details of Dividends						
		2016	2015				
		\$'000	\$'000				
	Interim Dividend						
	An unfranked Interim Dividend of 1.5 cents (2015: 1.5 cents) per share will be paid on 24 March 2017.	1,540	1,526				
6.	Dividend or Distribution reinvestment plans						
	There are no dividend or distribution reinvestment plans in operation.						
7.	Associates and joint venture entities There are no associates or relevant joint ventures.						
	Foreign Entity accounting standards						
8.							
0.	Not applicable						
9.	Audit Statement						
		This report is based on accounts to which one of the following applies.					
	(Tick one) ☐ The ⁺accounts have been x The ⁺ac audited. review.	ccounts have	been subject to				
		counts have <i>no</i> a or reviewed.	t yet been				

Sign here:

et

Peter T Kempen Chairman

Date: 17th February 2017